Displaying 1 - 4 of 4 items.

Green Fluorescent Protein

Green fluorescent protein (GFP) is a protein in the jellyfish Aequorea Victoria that exhibits green fluorescence when exposed to light. The protein has 238 amino acids, three of them (Numbers 65 to 67) form a structure that emits visible green fluorescent light. In the jellyfish, GFP interacts with another protein, called aequorin, which emits blue light when added with calcium. Biologists use GFP to study cells in embryos and fetuses during developmental processes.

Format: Articles

Subject: Technologies

Fate Map

Early development occurs in a highly organized and orchestrated manner and has long attracted the interest of developmental biologists and embryologists. Cell lineage, or the study of the developmental differentiation of a blastomere, involves tracing a particular cell (blastomere) forward from its position in one of the three germ layers. Labeling individual cells within their germ layers allows for a pictorial interpretation of gastrulation. This chart or graphical representation detailing the fate of each part of an early embryo is referred to as a fate map.

Format: Articles

Subject: Processes

Craig C. Mello (1960- )

Craig C. Mello is an American developmental biologist and Nobel Laureate, who helped discover RNA interference (RNAi). Along with his colleague Andrew Fire, he developed gene knockouts using RNAi. In 006 Mello won the Nobel Prize in Physiology or Medicine for his contribution. Mello also contributed to developmental biology, focusing on gene regulation, cell signaling, cleavage formation, germline determination, cell migration, cell fate differentiation, and morphogenesis.

Format: Articles

Subject: People

"Screening for Congenital Hypothyroidism" (1991), by Delbert A. Fisher

In his 1991 article Screening for Congenital Hypothyroidism, Delbert A. Fisher in the US reported on the implementation and impact of mass neonatal screening programs for congenital hypothyroidism (CH) from the early 1970s through 1991. CH is a condition that causes stunted mental and physical development in newborns unless treatment begins within the first three months of the newborn's life. In the early 1970s, regions in Canada and the US had implemented screening programs to diagnose and treat CH as quickly as possible after the infant's birth.

Format: Articles

Subject: Publications, Technologies